Abstract
Amphotericin B is the mainstay of therapy of many deep mycoses, but its use is seriously hampered by dose-limiting nephrotoxicity. In this study a liposomal formulation of amphotericin B was administered to ten patients with proven deep mycoses: invasive aspergillosis (n=4), deep candidiasis (n=4) and zygomycosis (n=2). The mean daily dosage of liposomal amphotericin B was 3.0 mg/kg (range 2.5 to 4 mg/kg), the mean total dosage of liposomal amphotericin B 2,781 mg (range 87 to 5,220 mg) and the mean duration of treatment 17 days (range 3 to 33 days). Treatment with liposomal amphotericin B was associated with little nephrotoxicity and an overall survival rate of 50 %. The median increase of serum creatinine from baseline levels was 0.38 mg/dl (−1.2 to 2.6 mg/dl).
Similar content being viewed by others
References
Beck Sagué CM, Jarvis WR, System NNIS: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. Journal of Infectious Diseases 1993, 167: 1247–1251.
Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Reviews of Infectious Diseases 1990, 12: 308–328.
Kennedy MS, Deeg MJ, Siegel M, Crowley JJ, Storb R, Thomas ED: Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983, 35: 211–215.
Brajtburg J, Powderly WG, Kobayashi GS, Medoff G:Amphotericin B: delivery systems. Antimicrobial Agents and Chemotherapy 1990, 34: 381–384.
Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey GP: Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. European Journal of Clinical Microbiology and Infectious Diseases 1991, 10: 665–668.
Tollemar J, Ringdén O: Early pharmacokinetic and clinical results from a noncomparative multicentre trial of amphotericin B encapsulated in a small unilamellar liposome (AmBisome). Drugs Investigation 1992, 4: 232–238.
Chopra R, Fielding A, Goldstone AH: Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome) — a report on 40 cases from a single centre. Leukemia and Lymphoma 1992, 7: 73–77.
Fisher EW, Toma A, Fisher PH, Cheesman AD: Rhinocerebral mucormycosis: use of liposomal amphotericin B. Journal of Laryngology and Otology 1991, 105: 575–577.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berenguer, J., Muñoz, P., Parras, F. et al. Treatment of deep mycoses with liposomal amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 13, 504–507 (1994). https://doi.org/10.1007/BF01974643
Issue Date:
DOI: https://doi.org/10.1007/BF01974643